|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
Á¦ ¸ñ |
imgNCWoUZNH |
|
ÀÌ ¸§ |
Sergio |
³¯ Â¥ |
2018/06/28 |
Á¶ ȸ |
2 |
|
It's OK anabeta elite buy Shares in Ranbaxy, which is majority-owned by Daiichi Sankyo, had been rising steadily since the news of that fine but this latest FDA ban has scuppered the stock, pushing it down over 30%. These means that the three plants in India the company uses to manufacture treatments for the USA cannot ship product to a market that makes up over 40% of Ranbaxy sales.
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|